SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral anti-diabetes agents, that can specifically bind to SGLT2 in the proximal renal tubule, reduce glucose reabsorption, promote urinary glucose excretion, and effectively reduce blood glucose [5].